18-Apr-2024
Proposed issue of securities - BXN
18-Apr-2024
Bioxyne Receives Firm Commitments to Raise $1.45 Million
29-Feb-2024
Half Yearly Report and Accounts
5-Feb-2024
BXN Awarded GMP Manufacturing License for Medical Cannabis
5-Feb-2024
Quarterly Report Listing Rule 4.7C.3
29-Jan-2024
Quarterly Activities/Appendix 4C Cash Flow Report
17-Nov-2023
Final Director's Interest Notice
17-Nov-2023
Retirement of Director
17-Nov-2023
Results of Meeting
17-Nov-2023
Annual General Meeting Presentation
31-Oct-2023
Quarterly Activities/Appendix 4C Cash Flow Report
19-Oct-2023
BLS Builds Medicinal Business In Australia
18-Oct-2023
Letter to Shareholders re Annual General Meeting Notice
18-Oct-2023
Notice of Annual General Meeting/Proxy Form
17-Oct-2023
Change of Director's Interest Notice
5-Oct-2023
AGM Date 2023 and Closing Date for Director Nominations
29-Sep-2023
Annual Report to shareholders
29-Sep-2023
Appendix 4G and Corporate Governance Statement
31-Aug-2023
Preliminary Final Report
31-Jul-2023
Quarterly Activities/Appendix 4C Cash Flow Report
17-Jul-2023
BLS Extends Amazon Footprint into US and Japan
22-May-2023
Bioxyne Completes Acquisition of Breathe Life Sciences
5-May-2023
Results of Meeting
24-Apr-2023
Quarterly Activities/Appendix 4C Cash Flow Report
20-Mar-2023
Bioxyne Executes SPA to Acquire Breathe Life Sciences
27-Feb-2023
Becoming a substantial holder
23-Feb-2023
Half Yearly Report and Accounts
27-Jan-2023
Quarterly Activities/Appendix 4C Cash Flow Report
19-Dec-2022
BXN to Acquire Health & Wellness Co Breathe Life Sciences
30-Nov-2022
New Constitution
28-Nov-2022
Results of Meeting
16-Nov-2022
Cleansing Notice
16-Nov-2022
Application for quotation of securities - BXN
15-Nov-2022
Proposed issue of securities - BXN
3-Nov-2022
Notification of cessation of securities - BXN
31-Oct-2022
Quarterly Activities/Appendix 4C Cash Flow Report
28-Oct-2022
Letter to Shareholders on Annual General Meeting Notice
28-Oct-2022
Notice of Annual General Meeting/Proxy Form
26-Oct-2022
Cleansing Notice
24-Oct-2022
Joins Asian Partner & Sells 49% of Direct Selling Business
30-Sep-2022
Appendix 4G and Corporate Governance Statement
30-Sep-2022
Annual Report to shareholders
30-Aug-2022
Preliminary Final Report
28-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report
30-Jun-2022
Initial Director's Interest Notice
30-Jun-2022
Final Director's Interest Notice
8-Jun-2022
Board and Management Changes
28-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
22-Feb-2022
Appendix 4D and Interim Report
31-Jan-2022
Quarterly Activities/Appendix 4C Cash Flow Report
30-Nov-2021
Results of Meeting
4-Nov-2021
Reinstatement to Official Quotation
4-Nov-2021
Bioxyne Not to Proceed with Proposed Acquisition
29-Oct-2021
Letter to Shareholders on Annual General Meeting
29-Oct-2021
Notice of Annual General Meeting/Proxy Form
29-Oct-2021
Suspension from Quotation
28-Oct-2021
Quarterly Activities/Appendix 4C Cash Flow Report
27-Oct-2021
Trading Halt
27-Oct-2021
Pause in Trading
30-Sep-2021
Appendix 4G and Corporate Governance Statement
30-Sep-2021
Annual Report to shareholders
30-Sep-2021
Explanatory Note to the 2021 Annual Report
31-Aug-2021
Preliminary Final Report
22-Jul-2021
Quarterly Activities/Appendix 4C Cash Flow Report
30-Apr-2021
Appendix 4C - quarterly
21-Apr-2021
Response to ASX Price Query
25-Feb-2021
Appendix 4D and Half Year Accounts
29-Jan-2021
Appendix 4C - Quarterly December 2020
26-Nov-2020
Results of Meeting
29-Oct-2020
Appendix 4C - quarterly
27-Oct-2020
Notice of Annual General Meeting/Proxy Form
30-Sep-2020
Appendix 4G and Corporate Governance
30-Sep-2020
Annual Report to shareholders
31-Aug-2020
Preliminary Final Report
21-Aug-2020
Response to ASX Price Query
31-Jul-2020
Appendix 4C - quarterly
1-May-2020
Appendix 4C Revised
30-Apr-2020
Appendix 4C - quarterly
14-Apr-2020
Market Update
28-Feb-2020
Appendix 4D and Half Year Accounts
31-Jan-2020
Appendix 4C - quarterly
20-Jan-2020
Change of Share Registry
27-Nov-2019
Change of Directors Interest Notice X 4
27-Nov-2019
Appendix 3B
25-Nov-2019
Results of Meeting
31-Oct-2019
Appendix 4C - quarterly
25-Oct-2019
Notice of Annual General Meeting/Proxy Form
9-Oct-2019
Change of Director's Interest Notice
30-Sep-2019
Annual Report to shareholders
30-Sep-2019
Explanatory Note to the 2019 Annual Report
30-Sep-2019
Appendix 4G and Corporate Governance Statement
28-Aug-2019
Preliminary Final Report
31-Jul-2019
Appendix 4C - quarterly
4-Jun-2019
Change of Director's Interest Notice
29-Apr-2019
Appendix 4C - quarterly
1-Apr-2019
Market Update
20-Feb-2019
Appendix 4D and Half Year Accounts
30-Jan-2019
Appendix 4C - quarterly
21-Jan-2019
Final Director's Interest Notice
17-Jan-2019
Director Resignation
21-Dec-2018
Change of Directors Interest Notice X 5
21-Dec-2018
Appendix 3B
29-Nov-2018
Results of Meeting
29-Oct-2018
Quarterly Activities Report
29-Oct-2018
Appendix 4C - quarterly
25-Oct-2018
Notice of Annual General Meeting/Proxy Form
16-Oct-2018
Change of Director's Interest Notice
28-Sep-2018
Annual Report to shareholders
28-Sep-2018
Appendix 4G and Corporate Governance Statement
25-Sep-2018
Bioxyne Expands to Indonesia with Acquisition
31-Aug-2018
Preliminary Final Report
6-Aug-2018
Change of Director's Interest Notice
27-Jul-2018
Quarterly Activities and Quarterly Cash Flow Report
16-Jul-2018
Change of Director's Interest Notice
10-Jul-2018
Change of Director's Interest Notice
22-Jun-2018
Change of Director's Interest Notice
20-Jun-2018
Change of Director's Interest Notice
12-Jun-2018
Bioxyne to Distribute GRAYNS Starch Reducing Rice Cooker
21-May-2018
Clarification to Announcement
21-May-2018
Expands to Thailand, Philippines, Myanmar, Cambodia,
4-May-2018
Initial Director's Interest Notice
1-May-2018
Appointment of Non-Executive Director
30-Apr-2018
Securities Trading Policy - Updated
27-Apr-2018
Quarterly Activities and Quarterly Cash Flow Reports
19-Mar-2018
Investor Update
1-Mar-2018
Response to ASX Query Letter
28-Feb-2018
Appendix 4D and Interim Financial Report
26-Feb-2018
Unique NZ Colostrum Honey Dairy Product for China and S.E.A
16-Feb-2018
Final Director's Interest Notice
15-Feb-2018
Director Resignation
15-Feb-2018
Appendix 3B Corrected
30-Jan-2018
Quarterly Activities and Quarterly Cash Flow Report Dec 17
17-Jan-2018
Change of Director's Interest Notice
16-Jan-2018
Additional New Products Launched for Direct Sales
19-Dec-2017
Appendix 3B
14-Dec-2017
Third Party Claim
11-Dec-2017
Appendix 3B
11-Dec-2017
Change of Directors Interest X 3
11-Dec-2017
Positive Bioxyne Gut Health Clinical Trial Results
7-Dec-2017
Change of Directors Interest Notice X 2
7-Dec-2017
Bioxyne Launches NZ Dairy Formula Product in South East Asia
7-Dec-2017
Appendix 3B Amended
5-Dec-2017
Appendix 3B
1-Dec-2017
Change of Share Registry
28-Nov-2017
Results of Meeting
15-Nov-2017
Letter to Optionholders
1-Nov-2017
Change of Director's Interest Notice
27-Oct-2017
Appendix 3B
26-Oct-2017
Notice of Annual General Meeting/Proxy Form
25-Oct-2017
Quarterly Activities Report and Appendix 4C
25-Oct-2017
Malaysian Direct Selling Licence to Propel Bioxyne into MLM
17-Oct-2017
Appendix 3B
16-Oct-2017
Response to ASX Price Query Letter
12-Oct-2017
Appendix 3B
25-Sep-2017
Appendix 4G
25-Sep-2017
Annual Report to shareholders
22-Sep-2017
Appendix 3B
18-Sep-2017
BXN Extends Product Range, New Website, Marketing Campaign
31-Aug-2017
Appendix 4E Preliminary Final Report
8-Aug-2017
Change in substantial holding
4-Aug-2017
Directors Change in Interest X 3
4-Aug-2017
Appendix 3B
3-Aug-2017
Results of Meeting
31-Jul-2017
Quarterly Activities Appendix 4C
11-Jul-2017
Appendix 3B
3-Jul-2017
Notice of General Meeting/Proxy Form
26-Jun-2017
Change in substantial holding
13-Jun-2017
Directors Initial Interest Notice X 2
13-Jun-2017
Becoming a substantial holder
13-Jun-2017
Appointment of Directors
1-Jun-2017
Share Sale Facility for Unmarketable Parcels
31-May-2017
Directors Change in Interest X 2
30-May-2017
Appendix 3B
26-May-2017
Rights Issue - Notification of Shortfall
8-May-2017
Appendix 3B
4-May-2017
Rights Issue - Letter to Ineligible Shareholders
3-May-2017
Letter to Shareholders - Rights Issue
3-May-2017
Prospectus - Rights Issue
27-Apr-2017
Quarterly Activities and Cash Flow Report March 2017
21-Apr-2017
Cleansing Statement
21-Apr-2017
Appendix 3B
19-Apr-2017
Letter to Optionholders
19-Apr-2017
Listing Rule 7.1A Information
19-Apr-2017
Appendix 3B
19-Apr-2017
Acquires NZ Product Company for Direct Sales Asia Pacific
13-Apr-2017
Trading Halt
27-Feb-2017
Appendix 4D and Half Year Report
21-Feb-2017
Bioxyne to Access Chinese Market for Online Sales via JD.com
8-Feb-2017
Response to ASX Appendix 3Y Letter
3-Feb-2017
Issue of Options, Appendix 3B, Appendix 3Y X 2
25-Jan-2017
Quarterly Activities and Cash Flow Report Dec 2016
13-Jan-2017
Change of Director's Interest Notice
29-Dec-2016
Details of Company Address
24-Nov-2016
Results of Meeting
23-Nov-2016
AGM Notice - Amendment to Resolutions
21-Nov-2016
AGM - Amendment to Resolutions
18-Nov-2016
Final Director's Interest Notice
18-Nov-2016
Director Resignation
2-Nov-2016
Launch of Two Products Containing PCC Onto Australian Market
26-Oct-2016
Quarterly Activities Report and Appendix 4C
24-Oct-2016
Notice of Annual General Meeting/Proxy Form
17-Oct-2016
Recruitment for Clinical Trial of Proprietary Probiotic PCC
29-Sep-2016
Annual Report to shareholders
29-Sep-2016
Appendix 4G and Corporate Governance Statement
12-Sep-2016
Becoming a substantial holder
9-Sep-2016
Ceasing to be a substantial holder
1-Sep-2016
Management Restructure
1-Sep-2016
Company Secretary Appointment/Details of Company Address
30-Aug-2016
Appendix 4E - Preliminary Final Report
28-Jul-2016
Appendix 4C - June Quarterly
23-Jun-2016
Bioxyne Commences New Clinical Trial
15-Jun-2016
Directors Equity Based Incentives
5-May-2016
Board Exercises Options
5-May-2016
Appendix 3B - Exercise of Directors' Options
5-May-2016
Change of Director's Interest Notice - Patrick Ford
5-May-2016
Change of Director's Interest Notice - Anthony Ho
5-May-2016
Change of Director's Interest Notice - George Cameron-Dow
26-Apr-2016
Appendix 4C - March quarterly
31-Mar-2016
Bioxyne Announces 2016 Goals
29-Mar-2016
Bioxyne Investor Presentation
16-Mar-2016
Change of Director's Interest Notice - A Ho
26-Feb-2016
Appendix 4D - Half Yearly Report and Accounts
15-Feb-2016
Initial Director's Interest Notice - Dr Peter French
15-Feb-2016
Appointment of Executive Director Dr Peter French
4-Feb-2016
Tony Ho - Change of Director's Interest Notice
21-Jan-2016
Appendix 4C - December Quarterly
20-Nov-2015
Results of Annual General Meeting
11-Nov-2015
Mariposa Health Inc. Investment Update
2-Nov-2015
Change of Director's Interest Notice - Patrick Ford
29-Oct-2015
Appendix 4C - September Quarterly
20-Oct-2015
2015 Notice of Annual General Meeting and Proxy Form
1-Oct-2015
Appendix 4G
30-Sep-2015
2015 Annual Report to Shareholders
31-Aug-2015
Appendix 4E - Preliminary Final Report
17-Aug-2015
2015 Financial Year Profit Update
30-Jul-2015
Appendix 4C - June Quarterly
20-May-2015
Becoming a Substantial Holder - Ondek Pty Ltd
20-May-2015
Change of Director's Interest Notice - George Cameron-Dow
20-May-2015
Ceasing to be a substantial holder - Fleming
28-Apr-2015
Appendix 4C - March Quarterly
16-Apr-2015
Change of Director's Interest Notice - George Cameron-Dow
27-Feb-2015
Appendix 4D - Half Yearly Report and Accounts
10-Feb-2015
Change of Director's Interest Notice - P Ford
30-Jan-2015
Change of Director's Interest Notice - A Ho
28-Jan-2015
Appendix 4C - December Quarterly
11-Dec-2014
Change of Director's Interest Notice - A Ho
11-Dec-2014
Change of Director's Interest Notice - P Ford
11-Dec-2014
Change of Director's Interest Notice - G Cameron-Dow
11-Dec-2014
Appendix 3B - Issue of Employee Options
28-Nov-2014
Change of Registered Office
28-Nov-2014
Results of 2014 Annual General Meeting
24-Nov-2014
Change of Director's Interest Notice - P Ford
21-Nov-2014
Change of Director's Interest Notice - A Ho
29-Oct-2014
Notice of 2014 Annual General Meeting/Proxy Form
27-Oct-2014
Appendix 4C - September Quarterly
30-Sep-2014
Annual Report to Shareholders
18-Sep-2014
Appointment of Strategic Marketing Consultant
29-Aug-2014
Appendix 4E - Preliminary Final Report
19-Aug-2014
Top 20 securityholders
28-Jul-2014
Appendix 4C - June Quarterly
21-Jul-2014
Initial Director's Interest Notice - George Cameron-Dow
21-Jul-2014
Final Director's Interest Notice - Jeremy Curnock-Cook
21-Jul-2014
Resignation and Appointment of Directors
21-Jul-2014
Change of Director's Interest Notice - Jeremy Curnock-Cook
21-Jul-2014
Ceasing to be substantial holder - Phillip Asset Management
21-Jul-2014
Becoming a substantial holder - Fleming SG Capital SO
16-May-2014
Options Expiry
30-Apr-2014
Appendix 4C - March Quarterly
4-Apr-2014
Appendix 3B - Quotation Following ASX Escrow Release
1-Apr-2014
Change of Director's Interest Notice - P Ford
18-Mar-2014
Release of Shares from Escrow
28-Feb-2014
Half Yearly Report and Accounts
25-Feb-2014
Change of Director's Interest Notice - P Ford
25-Feb-2014
Completion of the Sale of HI-164 Program
19-Feb-2014
Change of Director's Interest Notice - P Ford
14-Feb-2014
Change in substantial holding
31-Jan-2014
Appendix 4C - December Quarterly
31-Jan-2014
Amended Change of Director's Interest Notices
30-Jan-2014
Change of Director's Interest Notice - P Ford
30-Jan-2014
Change of Director's Interest Notice - J C Cook
30-Jan-2014
Change of Director's Interest Notice - A P Ho
27-Dec-2013
Appendix 3B - EGM Approved Share and Option Issues
23-Dec-2013
Results of EGM
4-Dec-2013
Expiry of Unquoted Options
2-Dec-2013
Bioxyne Limited CEO Steps Down
2-Dec-2013
Sale of HI-164OV Hunter Immunology Pty Ltd
29-Nov-2013
Results of 2013 AGM
22-Nov-2013
Notice of Extraordinary General Meeting/Proxy Form
6-Nov-2013
Response to ASX query
31-Oct-2013
Appendix 4C - September Quarterly
31-Oct-2013
Notice of Annual General Meeting/Proxy Form
23-Sep-2013
30 June 2013 Full Year Statutory Accounts
30-Aug-2013
Appendix 4E - Preliminary Final Report
6-Aug-2013
Response to ASX query
31-Jul-2013
Appendix 4C - June Quarterly
6-Jun-2013
Company Secretary Resignation
23-May-2013
Termination of proposed acquisition - Vitality Devices
30-Apr-2013
Appendix 4C - quarterly - 31 March 2013
4-Apr-2013
Appendix 3B - Quotation of Escrowed Stock
15-Mar-2013
Release of Shares from Escrow
7-Mar-2013
Appendix 3B and s708A(6) Notice - Completion of Placement
4-Mar-2013
Vitality Devices Acquisition Update
28-Feb-2013
Half Yearly Report and Accounts to 31 December 2012
20-Feb-2013
Completion of placement follow up
20-Feb-2013
Reinstatement to Official Quotation
20-Feb-2013
Completion of Placement
20-Feb-2013
Suspension Request
20-Feb-2013
Suspension from Official Quotation
18-Feb-2013
Appointment of new CFO and change of registered office
18-Feb-2013
Trading Halt
18-Feb-2013
Proposed Acquisition of Vitality
18-Feb-2013
Status Review HI 164OV Further Update
12-Feb-2013
Appoints New Company Secretary
5-Feb-2013
Response to ASX query
31-Jan-2013
Appendix 4C - quarterly
25-Jan-2013
Change of Director's Interest Notice
21-Jan-2013
Update and Status review of HI-164 therapy for COPD
11-Jan-2013
Change of Director's Interest Notice
17-Dec-2012
Final Director's Interest Notice
17-Dec-2012
Initial Director's Interest Notice
13-Dec-2012
APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND NEW DIRECTOR
3-Dec-2012
Change in Board Composition
3-Dec-2012
Final Director's Interest Notice
3-Dec-2012
Final Director's Interest Notice - IM
29-Nov-2012
BIOXYNE Results of Meeting 20121129
29-Nov-2012
AGM Presentation 29 November 2012 BXN
28-Nov-2012
Extra Ordinary General Meeting To Set Future Direction
20-Nov-2012
BioxyneCuts Costs To Focus On New Study
12-Nov-2012
Bioxyne's Board Renewal
5-Nov-2012
Initial Director's Interest Notice
1-Nov-2012
Final Director's Interest Notice
31-Oct-2012
Final Director's Interest Notice
31-Oct-2012
Appendix 4C - quarterly
30-Oct-2012
Results of Meeting
29-Oct-2012
Notice of Annual General Meeting/Proxy Form
26-Oct-2012
Final Director's Interest Notice
25-Oct-2012
Director's Resignation
24-Oct-2012
Shareholder Update
8-Oct-2012
Amended Change of Director's Interest Notice
5-Oct-2012
Change of Director's Interest Notice
28-Sep-2012
Annual Report to shareholders
24-Sep-2012
Bioxyne enters Heads of Agreement
20-Sep-2012
Notice of General Meeting/Proxy Form
31-Aug-2012
Preliminary Final Report
31-Aug-2012
Notice of Requisition of Meeting from Wigram Trading Pty Ltd
27-Aug-2012
Requisition of Meeting from Octa Philip Asset Management
27-Aug-2012
Requisition of Shareholders Meeting
27-Jul-2012
Appendix 4C - quarterly
17-Jul-2012
Chairman's Address - slides
12-Jul-2012
Investor Presentation
12-Jul-2012
Update On Commercialisation Process
6-Jul-2012
Chairman's Letter
28-Jun-2012
Top 20 securityholders
28-Jun-2012
Appendix 3B
28-Jun-2012
Reinstatement to official quotation
28-Jun-2012
Results of Phase 2b Study
25-Jun-2012
Market Update On Suspension of Shares
15-Jun-2012
Suspension from Official Quotation
13-Jun-2012
Trading Halt
28-May-2012
On Track To Report Clinical Trial Results In June
23-May-2012
Appointment of Torreya Partners LLC
8-May-2012
Initial Director's Interest Notice Jeremy L Curnock Cook
26-Apr-2012
Investor Presentation
24-Apr-2012
Quarterly Update and Appendix 4C
18-Apr-2012
Becoming a substantial holder
18-Apr-2012
Initial Director's Interest Notice
16-Apr-2012
Becoming a substantial holder
13-Apr-2012
Becoming a substantial holder
13-Apr-2012
New Listed Drug Developer Bioxyne Postioned For Growth
10-Apr-2012
Final Director's Interest Notice - Simon Taylor
10-Apr-2012
Final Director's Interest Notice - Simon O'Loughlin
10-Apr-2012
Initial Director's Interest Notice - William Harrison
10-Apr-2012
Change of Director's Interest Notice - P Ford
10-Apr-2012
Initial Director's Interest Notice - Glenn Crisp
10-Apr-2012
Initial Director's Interest Notice - David Radford
10-Apr-2012
Initial Director's Interest Notice - Ian Mutton
4-Apr-2012
Becoming a substantial holder
4-Apr-2012
New Australian Drug Developer Lists on ASX
4-Apr-2012
Becoming a substantial holder
3-Apr-2012
Share Trading Policy
3-Apr-2012
Constitution of Company
3-Apr-2012
Completion of Takeover of Hunter Immunology Limited
3-Apr-2012
Pre-Quotation Disclosure
3-Apr-2012
Becoming a substantial holder
3-Apr-2012
Reinstatement to Official Quotation (04/04/12)
3-Apr-2012
ASX Circular - Reinstatement to Official List
2-Apr-2012
Change of Company Name to Bioxyne Limited
28-Mar-2012
Appendix 3B
28-Mar-2012
Top 20 securityholders
28-Mar-2012
Range of Shares
28-Mar-2012
Top 20 Option Holders
23-Mar-2012
Completion of Takeover Offers and Compulsory Acquisition
16-Mar-2012
Results of Meeting
15-Mar-2012
Notification of Amended Timetable for Re-admission to ASX
14-Mar-2012
Share Consolidation
2-Mar-2012
Achievement of Minimum Subscription under Public Offer
29-Feb-2012
Half Yearly Report and Accounts
7-Feb-2012
Correction to Chairman's Address at General Meeting
7-Feb-2012
Suspension from Official Quotation
7-Feb-2012
Results of Meeting
7-Feb-2012
Chairman's Address Delivered At The General Meeting
7-Feb-2012
Trading Halt
6-Feb-2012
Chairman's Address to Shareholders - Gen Meeting 7 Feb 2012
3-Feb-2012
Extension Of Public Offer Period
30-Jan-2012
First Supplementary Target's Statement By Hunter Immunology
25-Jan-2012
Appendix 4C - quarterly
24-Jan-2012
First Supplementary Bidder's Statement for Hunter Immunology
6-Jan-2012
Replacement Prospectus
6-Jan-2012
Notice of General Meeting/Proxy Form
22-Dec-2011
Notice of Dispatch of Bidder's Statement
21-Dec-2011
Replacement Prospectus
20-Dec-2011
Appendix 3B Replacement Options
15-Dec-2011
Target's Statement
14-Dec-2011
Appendix 3B Public Offer
13-Dec-2011
Bidder's Statement for Hunter Immunology Ltd
13-Dec-2011
Prospectus to Raise a Maximum of $ 4,400,000
9-Dec-2011
Issue Of Bidder's Statement in Connection with Takeover Bid
30-Nov-2011
Section 708 A (6) Notice and Appendix 3B
29-Nov-2011
Results of Meeting
29-Nov-2011
Chairman's Address to Shareholders
3-Nov-2011
Placement
2-Nov-2011
Termination of Agreement with Nestec
25-Oct-2011
Appendix 4C - quarterly
21-Oct-2011
Notice of Annual General Meeting/Proxy Form
12-Oct-2011
Reinstatement to Official Quotation
11-Oct-2011
Proposed Merger Of Probiomics with Hunter Immunology
11-Oct-2011
Suspension from Official Quotation
7-Oct-2011
Trading Halt
27-Sep-2011
Annual Report to shareholders
30-Aug-2011
Preliminary Final Report
29-Jul-2011
Appendix 4C - quarterly
2-May-2011
PCC Response to ASX Query
21-Apr-2011
Appendix 4C - quarterly
28-Feb-2011
Half Yearly Report and Accounts
28-Jan-2011
Appendix 4C - quarterly
21-Dec-2010
Share Trading Policy
16-Nov-2010
Results of Meeting
16-Nov-2010
Chairman's Address to Shareholders
29-Oct-2010
Registration of PCC in New Zealand for Companion Animals
25-Oct-2010
Appendix 4C - quarterly
27-Sep-2010
Repayment Of Convertible Notes
22-Sep-2010
Annual Report to shareholders
16-Sep-2010
Notice of Annual General Meeting/Proxy Form
20-Aug-2010
Preliminary Final Report
19-Jul-2010
Appendix 4C - quarterly
11-May-2010
Press Release Chr Hansen to showcase PCC at Vitafoods Geneva
11-May-2010
Chr. Hansen to introduce PCC at Vitafoods Geneva
30-Apr-2010
Appendix 4C - quarterly
26-Feb-2010
Half Yearly Report and Accounts
28-Jan-2010
Appendix 4C - quarterly
26-Nov-2009
Results of Meeting
25-Nov-2009
Chairman's Address to Shareholders
24-Nov-2009
CHR HANSEN PRESS RELEASE ON THE GLOBAL AGREEMENT
24-Nov-2009
PROBIOMICS SIGNS AN EXCLUSIVE AGREEMENT WITH CHR. HANSEN
23-Nov-2009
Trading Halt
27-Oct-2009
Change of Director's Interest Notice
20-Oct-2009
Appendix 4C - quarterly
14-Oct-2009
Notice of Annual General Meeting/Proxy Form
6-Oct-2009
Change of Director's Interest Notice
30-Sep-2009
Change of Director's Interest Notice - Simon O'Loughlin
30-Sep-2009
Change of Director's Interest Notice - Simon Taylor
28-Sep-2009
Annual Report For The Year Ended 30 June 2009
25-Aug-2009
PCC Effective In Reducing Illness in Athletes
18-Aug-2009
Preliminary Final Report
5-Aug-2009
Extension of Convertible Notes
31-Jul-2009
Resignation of CEO
21-Jul-2009
Quarterly Cashflow Report
26-May-2009
Section 708A(6) Notice and Appendix 3B
19-May-2009
Change of Director's Interest Notice
15-May-2009
Results of Meeting
12-May-2009
Private Placement
12-May-2009
PCC Shown To Be Effective In Boosting Flu Vaccine In Trial
30-Apr-2009
Appendix 4C - quarterly
2-Apr-2009
Notice of General Meeting/Proxy Form
27-Feb-2009
Half Yearly Report and Accounts
13-Jan-2009
Appendix 4C - quarterly
5-Dec-2008
Appendix 3B
1-Dec-2008
Expiry of Unlisted Options
27-Nov-2008
Change Of Director's Interest - S O'Loughlin
27-Nov-2008
Change Of Director's Interest - S Taylor
27-Nov-2008
Change Of Director's Interest - P Ford
27-Nov-2008
Appendix 3B
27-Nov-2008
Results of Meeting
26-Nov-2008
Chairman's Address to Shareholders
27-Oct-2008
Appendix 4C - quarterly
21-Oct-2008
Notice of Annual General Meeting/Proxy Form
30-Sep-2008
Annual Report 2008
15-Sep-2008
Expiry of Unquoted Options and Extention of Con Notes
4-Sep-2008
Response to ASX Query
27-Aug-2008
Preliminary Final Report
22-Aug-2008
Appendix 3B
22-Aug-2008
Class Order Relief
8-Aug-2008
Resignation Of Directors
8-Aug-2008
Final Director's Interest Notice
7-Aug-2008
Final Director's Interest Notice
6-Aug-2008
Final Director's Interest Notice
6-Aug-2008
Initial Director's Interest Notice
5-Aug-2008
Initial Director's Interest Notice
5-Aug-2008
Initial Director's Interest Notice
31-Jul-2008
Market Update and Board Changes
31-Jul-2008
Quarterly Cashflow Report
27-Jun-2008
Change of Director's Interest Notice
27-Jun-2008
Appendix 3B
24-Jun-2008
Results of Meeting
24-Jun-2008
Change of Registered Office Address
23-Jun-2008
Chairman's Address to Shareholders
13-May-2008
Notice of Annual General Meeting/Proxy Form
30-Apr-2008
Commitments Test Entity - Third Quarter Report
24-Apr-2008
Extension of Share Purchase Plan
18-Apr-2008
Extension of Share Purchase Plan Offer
16-Apr-2008
Market Update - Acquisition of Minomic International Limited
7-Apr-2008
Market Update
20-Mar-2008
Newsletter
13-Mar-2008
Share Purchase Plan Offer Booklet and Application Form
13-Mar-2008
Conditional acquisition of Minomic International Limited
11-Mar-2008
Appointment of New Chief Executive Officer
4-Mar-2008
Reinstatement to Official Quotation
3-Mar-2008
Half Year Accounts
29-Feb-2008
4 D - Half Yearly Report
27-Feb-2008
Capital Raising Update
31-Jan-2008
Commitments Test Entity - Second Quarter Report
20-Dec-2007
Appendix 3B
25-Oct-2007
Commitments Test Entity - First Quarter Report
15-Oct-2007
Executes Global Finance Agreement with Nestle
10-Oct-2007
Issue of Convertible Notes
28-Sep-2007
Annual Report to shareholders
31-Aug-2007
Preliminary Final Report
30-Jul-2007
Commitments Test Entity - Fourth Quarter Report
27-Jul-2007
Company Secretary Appointment
1-Jun-2007
Issue of Unlisted Options
3-May-2007
Lapse of Unlisted Options
23-Apr-2007
Class order relief for share placement
18-Apr-2007
Commitments Test Entity - Third Quarter Report
13-Apr-2007
Appendix 3B
23-Mar-2007
Share Placement
1-Mar-2007
Lapse of unlisted employee options
28-Feb-2007
Half Yearly Report & Accounts
31-Jan-2007
Commitments Test Entity - Second Quarter Report
1-Dec-2006
Issue of employee options
29-Nov-2006
Results of AGM
31-Oct-2006
Commitments Test Entity - First Quarter Report
25-Oct-2006
Notice of Annual General Meeting
6-Oct-2006
Lapse of Unlisted Options
28-Sep-2006
2006 Annual Report
22-Sep-2006
Ceasing to be a substantial holder
21-Sep-2006
Issue of Options
21-Sep-2006
Results of General Meeting
13-Sep-2006
Preliminary Final Report
15-Aug-2006
Notice of General Meeting
14-Aug-2006
Class Order Relief for Placement of Shares
9-Aug-2006
Appendix 3B
31-Jul-2006
Commitments Test Entity - Fourth Quarter Report
3-Jul-2006
Lapse of Options
7-Jun-2006
Issue of employee share options
27-Apr-2006
Commitments Test Entity - Third Quarter Report
11-Apr-2006
Quarterly Newsletter
9-Mar-2006
Half Yearly Report & Half Year Accounts
7-Mar-2006
Lapse of listed options
2-Mar-2006
Re-negotiates distribution contract
30-Jan-2006
Commitments Test Entity - Second Quarter Report
16-Jan-2006
Issue of options to Directors
12-Dec-2005
Change of Director's Interest Notice
12-Dec-2005
Clarification of media report on clinical trial
8-Dec-2005
Appendix 3B
8-Dec-2005
Lapse of employee share options
24-Nov-2005
Results of AGM
24-Nov-2005
Chairman's AGM Address to Shareholders
24-Nov-2005
Extension of closing date of SPP
23-Nov-2005
Flu vaccine clinical trial
16-Nov-2005
Wins AJP Award
8-Nov-2005
Receipt of Commercial Ready grant
31-Oct-2005
Commitments Test Entity - First Quarter Report
31-Oct-2005
Share Purchase Plan - Letter to Shareholders
20-Oct-2005
Notice of Annual General Meeting
30-Sep-2005
2005 Annual Report
23-Sep-2005
Becoming a substantial holder
23-Sep-2005
Becoming a substantial holder
13-Sep-2005
Preliminary Final Report
24-Aug-2005
Class order relief statement
22-Aug-2005
Appendix 3B - Share Placement
29-Jul-2005
Commitments Test Entity - Fourth Quarter Report
29-Jul-2005
$1m Private Placement
5-Jul-2005
Quarterly Newsletter to Shareholders
24-May-2005
Final Director's Interest Notice
24-May-2005
Appendix 3B - Issue of unlisted employee share options
24-May-2005
Final Director's Interest Notice
24-May-2005
Initial Director's Interest Notice
20-May-2005
Board Changes & AIM Listing
13-May-2005
Placement - ASIC Class Order Relief
12-May-2005
Appendix 3B - Additional Working Capital
2-May-2005
Amendment to previous announcement re Placement
2-May-2005
Change of Trading Code to PCC
2-May-2005
Fully Underwritten $1.0 million Placement & SPP
2-May-2005
Commitments Test Entity - Third Quarter Report
19-Apr-2005
Lapse of Employee Options
11-Apr-2005
Appendix 3B - Issue of Employee Share Options
8-Apr-2005
Results of General Meeting
22-Mar-2005
Investor Presentation
16-Mar-2005
Response to ASX Query
15-Mar-2005
Product Launch boosted as FDA clamps down on competitors
9-Mar-2005
Successful Completion-1st Stage Molecule Discovery Program
3-Mar-2005
Initial Director's Interest Notice
3-Mar-2005
Notice of General Meeting
3-Mar-2005
Initial Director's Interest Notice
3-Mar-2005
Initial Director's Interest Notice
3-Mar-2005
Final Director's Interest Notice
3-Mar-2005
Final Director's Interest Notice
25-Feb-2005
Half Yearly Report & Half Year Accounts
23-Feb-2005
Second Functional Food Agreement
21-Feb-2005
Ceasing to be a substantial holder
18-Feb-2005
Board Changes for AIM admission
18-Feb-2005
Partners with Sanitarium
15-Feb-2005
Trial to reduce ear infections in Aboriginal children
9-Feb-2005
Becoming a substantial holder
7-Feb-2005
Becoming a substantial holder
31-Jan-2005
Commitments Test Entity - Second Quarter Report
31-Jan-2005
VRI to List on AIM
25-Jan-2005
Licensing Agreement with Largest Distributor in Asia
30-Nov-2004
Form 484 - Selective reduction of capital
26-Nov-2004
Appendix 3B - issue of options to a director
26-Nov-2004
Final Director's Interest Notice
26-Nov-2004
Results of AGM
17-Nov-2004
Presentation to Investors
28-Oct-2004
Commitments Test Entity - First Quarter Report
25-Oct-2004
Notice of AGM & Special Meeting
25-Oct-2004
Annual Report 2004
30-Sep-2004
Annual Report
28-Sep-2004
Rowett Research Institute project
31-Aug-2004
Preliminary Final Report
26-Aug-2004
Significant interest in Atopic Dermatitis Trial Results
11-Aug-2004
Lapse of Options
30-Jul-2004
App 3B -Part consideration for arranging placement of shares
30-Jul-2004
Commitments Test Entity - Fourth Quarter Report
27-Jul-2004
Appendix 3B - New issue
27-Jul-2004
Disclosure Document
20-Jul-2004
Amended Appendix 3B - For additional funding of operations
20-Jul-2004
Placement - ASIC Class Order Relief
20-Jul-2004
Appendix 3B - For additional funding of company's operations
14-Jul-2004
successful Phase II Trial Results for Atopic Dermatitis
12-Jul-2004
Results of Meeting
6-Jul-2004
Ceasing to be a substantial holder
5-Jul-2004
Death of Mr Jim Grant -Chairman
21-Jun-2004
Change in substantial holding
15-Jun-2004
Issue of Bonus Options to Shareholders
11-Jun-2004
Chairman's Letter to Shareholders/Notice of General Meeting
28-May-2004
Placement
12-May-2004
Launches new proTract range of Probiotics
7-May-2004
Registration of Progastrim in Singapore
4-May-2004
Appointment of Medical & Scientific Advisory Board
29-Apr-2004
Commitments Test Entity - Third Quarter Report
30-Mar-2004
Appendix 3B - Fund companys operations
29-Mar-2004
Placement & Forthcoming Rights Issue raising $2.9m
15-Mar-2004
Advances Plans for Product Distribution in Asia & US
27-Feb-2004
Shareholder Update from Managing Director
27-Feb-2004
Half Yearly Report & Half Year Accounts
5-Feb-2004
Response to ASX Appendix 4C Query
28-Jan-2004
Commitments Test Entity - Second Quarter Report
21-Jan-2004
Ceasing to be a substantial holder